{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:14:34Z","timestamp":1790806474494,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T00:00:00Z","timestamp":1675728000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.jval.2023.01.016","type":"journal-article","created":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T02:00:09Z","timestamp":1675389609000},"page":"909-917","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Current Health State Affected Patient Preferences More Than Disease Status: A Discrete Choice Experiment in Multiple Myeloma"],"prefix":"10.1016","volume":"26","author":[{"given":"Tommi","family":"Tervonen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Duenas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Collacott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharine S.","family":"Gries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Carson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Trevor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Krucien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianming","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jval.2023.01.016_bib1","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.drudis.2018.09.015","article-title":"Factors and situations influencing the value of patient preference studies along the medical\u00a0product lifecycle: a literature review","volume":"24","author":"van Overbeeke","year":"2019","journal-title":"Drug Discov Today"},{"issue":"5","key":"10.1016\/j.jval.2023.01.016_bib2","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s40271-017-0235-y","article-title":"Patients\u2019 preferences for outcome, process and cost attributes in cancer treatment: a systematic review of discrete choice experiments","volume":"10","author":"Bien","year":"2017","journal-title":"Patient"},{"issue":"15","key":"10.1016\/j.jval.2023.01.016_bib3","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1002\/cncr.32961","article-title":"Importance of quality-of-life priorities and preferences surrounding treatment decision making in patients with cancer and oncology clinicians","volume":"126","author":"Williams","year":"2020","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.jval.2023.01.016_bib4","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s40271-021-00520-4","article-title":"A\u00a0systematic review of discrete choice experiments in oncology treatments","volume":"14","author":"Collacott","year":"2021","journal-title":"Patient"},{"issue":"6","key":"10.1016\/j.jval.2023.01.016_bib5","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.jpainsymman.2019.01.016","article-title":"The stability of treatment preferences among patients with advanced cancer","volume":"57","author":"Jabbarian","year":"2019","journal-title":"J\u00a0Pain Symptom Manage"},{"issue":"2","key":"10.1016\/j.jval.2023.01.016_bib6","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1200\/JCO.2000.18.2.421","article-title":"Impact of quality of life on patient expectations regarding phase I clinical trials","volume":"18","author":"Cheng","year":"2000","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.jval.2023.01.016_bib7","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1136\/thoraxjnl-2019-213974","article-title":"Maintenance inhaler therapy preferences of patients with asthma or chronic obstructive pulmonary disease: a discrete choice experiment","volume":"75","author":"Tervonen","year":"2020","journal-title":"Thorax"},{"issue":"2","key":"10.1016\/j.jval.2023.01.016_bib8","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s40271-021-00548-6","article-title":"Comparing patient preferences for antithrombotic treatment during the acute and chronic phases of myocardial infarction: a discrete-choice experiment","volume":"15","author":"Pinto","year":"2022","journal-title":"Patient"},{"issue":"4","key":"10.1016\/j.jval.2023.01.016_bib9","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2165\/1312067-200801040-00012","article-title":"How does patients\u2019 quality of life guide their preferences regarding aspects of asthma therapy?: a patient-preference study using discrete-choice experiment methodology","volume":"1","author":"Lloyd","year":"2008","journal-title":"Patient"},{"key":"10.1016\/j.jval.2023.01.016_bib10","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.2147\/PPA.S142373","article-title":"The impact of quality of life on treatment preferences in multiple sclerosis patients","volume":"11","author":"Lee Mortensen","year":"2017","journal-title":"Patient Prefer Adherence"},{"issue":"11","key":"10.1016\/j.jval.2023.01.016_bib11","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"10272","key":"10.1016\/j.jval.2023.01.016_bib12","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple myeloma","volume":"397","author":"van de Donk","year":"2021","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.jval.2023.01.016_bib13","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s40271-021-00501-7","article-title":"Patient perceptions regarding multiple myeloma and its treatment: qualitative evidence from interviews with patients in the United Kingdom, France, and Germany","volume":"14","author":"He","year":"2021","journal-title":"Patient"},{"issue":"3","key":"10.1016\/j.jval.2023.01.016_bib14","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10198-010-0218-6","article-title":"Analysis of physicians\u2019 perspectives versus patients\u2019 preferences: direct assessment and discrete choice experiments in the therapy of multiple myeloma","volume":"12","author":"M\u00fchlbacher","year":"2011","journal-title":"Eur J Health Econ"},{"issue":"1","key":"10.1016\/j.jval.2023.01.016_bib15","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1634\/theoncologist.2017-0257","article-title":"Individual trade-offs between possible benefits and risks of cancer treatments: results from a stated preference study with patients with multiple myeloma","volume":"23","author":"Postmus","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.jval.2023.01.016_bib16","article-title":"Patient preferences for multiple myeloma treatments: a multinational qualitative study","volume":"8","author":"Janssens","year":"2021","journal-title":"Front Med (Lausanne)"},{"issue":"10","key":"10.1016\/j.jval.2023.01.016_bib17","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual Life Res"},{"issue":"1","key":"10.1016\/j.jval.2023.01.016_bib18","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/hec.3564","article-title":"Valuing health-related quality of life: an EQ-5D-5L value set for England","volume":"27","author":"Devlin","year":"2018","journal-title":"Health Econ"},{"key":"10.1016\/j.jval.2023.01.016_bib19","series-title":"Discrete Choice Methods With Simulation","author":"Train","year":"2012"},{"issue":"5","key":"10.1016\/j.jval.2023.01.016_bib20","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s40271-018-0304-x","article-title":"Accounting for scale heterogeneity in healthcare-related discrete choice experiments when comparing stated preferences: a systematic review","volume":"11","author":"Wright","year":"2018","journal-title":"Patient"},{"issue":"2","key":"10.1016\/j.jval.2023.01.016_bib21","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s40271-017-0282-4","article-title":"Scale heterogeneity in healthcare discrete choice experiments: a primer","volume":"11","author":"Vass","year":"2018","journal-title":"Patient"},{"issue":"3","key":"10.1016\/j.jval.2023.01.016_bib22","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2307\/2683166","article-title":"The likelihood ratio, Wald, and Lagrange multiplier tests - an expository note","volume":"36","author":"Buse","year":"1982","journal-title":"Am Stat"},{"issue":"10","key":"10.1016\/j.jval.2023.01.016_bib23","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1002\/hec.984","article-title":"Effects coding in discrete choice experiments","volume":"14","author":"Bech","year":"2005","journal-title":"Health Econ"},{"issue":"5","key":"10.1016\/j.jval.2023.01.016_bib24","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s40271-021-00506-2","article-title":"Patient preferences of low-dose aspirin for cardiovascular disease and colorectal cancer prevention in Italy: a latent class analysis","volume":"14","author":"Tervonen","year":"2021","journal-title":"Patient"},{"issue":"10","key":"10.1016\/j.jval.2023.01.016_bib25","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.jval.2018.04.1822","article-title":"Assessing rationality in discrete choice experiments in health: an investigation into the use of dominance tests","volume":"21","author":"Tervonen","year":"2018","journal-title":"Value Health"},{"issue":"5","key":"10.1016\/j.jval.2023.01.016_bib26","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/ejh.12790","article-title":"Prevalence of symptoms in patients with multiple myeloma: a systematic review and meta-analysis","volume":"97","author":"Ramsenthaler","year":"2016","journal-title":"Eur J Haematol"},{"issue":"4","key":"10.1016\/j.jval.2023.01.016_bib27","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/ajh.26480","article-title":"Health-related quality of life in patients with relapsed\/refractory multiple myeloma treated with pomalidomide and dexamethasone \u00b1 subcutaneous daratumumab: patient-reported outcomes from the Apollo trial","volume":"97","author":"Terpos","year":"2022","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.jval.2023.01.016_bib28","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1186\/s12885-021-08325-2","article-title":"Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial","volume":"21","author":"Knop","year":"2021","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.jval.2023.01.016_bib29","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1200\/JCO.20.01370","article-title":"Health-related quality of life in transplant-ineligible patients with newly diagnosed multiple myeloma: findings from the Phase III Maia trial","volume":"39","author":"Perrot","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.jval.2023.01.016_bib30","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s00432-020-03365-w","article-title":"Greater treatment satisfaction in patients receiving daratumumab subcutaneous vs. intravenous for relapsed or refractory multiple myeloma: COLUMBA clinical trial results","volume":"147","author":"Usmani","year":"2021","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"issue":"8","key":"10.1016\/j.jval.2023.01.016_bib31","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.1111\/bcp.15309","article-title":"Multimethod quantitative benefit-risk assessment of treatments for moderate-to-severe osteoarthritis","volume":"88","author":"Mauer","year":"2022","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"10.1016\/j.jval.2023.01.016_bib32","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-021-00543-y","article-title":"Review of patient-reported outcomes in multiple myeloma registrational trials: highlighting areas for improvement","volume":"11","author":"Fernandes","year":"2021","journal-title":"Blood Cancer J"},{"issue":"5","key":"10.1016\/j.jval.2023.01.016_bib33","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.jval.2012.02.008","article-title":"Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets","volume":"15","author":"van Hout","year":"2012","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.jval.2023.01.016_bib34","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1016\/j.clml.2018.08.019","article-title":"Health-related quality of life of patients with multiple myeloma treated in routine clinical practice in France","volume":"19","author":"Despi\u00e9gel","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301523000414?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301523000414?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T01:31:50Z","timestamp":1761096710000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301523000414"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S1098301523000414"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2023.01.016","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current Health State Affected Patient Preferences More Than Disease Status: A Discrete Choice Experiment in Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2023.01.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}